Zosano Pharma Corporation (ZSAN): Price and Financial Metrics
GET POWR RATINGS... FREE!
ZSAN POWR Grades
- Growth is the dimension where ZSAN ranks best; there it ranks ahead of 82.49% of US stocks.
- The strongest trend for ZSAN is in Quality, which has been heading up over the past 113 days.
- ZSAN ranks lowest in Quality; there it ranks in the 1st percentile.
ZSAN Stock Summary
- With a market capitalization of $35,662,809, Zosano Pharma Corp has a greater market value than only 6.61% of US stocks.
- With a price/sales ratio of 45.43, Zosano Pharma Corp has a higher such ratio than 95.86% of stocks in our set.
- Revenue growth over the past 12 months for Zosano Pharma Corp comes in at 250.45%, a number that bests 96.65% of the US stocks we're tracking.
- Stocks that are quantitatively similar to ZSAN, based on their financial statements, market capitalization, and price volatility, are INFI, ATNM, LCTX, SONN, and BBI.
- ZSAN's SEC filings can be seen here. And to visit Zosano Pharma Corp's official web site, go to www.zosanopharma.com.
ZSAN Valuation Summary
- In comparison to the median Healthcare stock, ZSAN's price/earnings ratio is 107.12% lower, now standing at -2.6.
- Over the past 80 months, ZSAN's price/sales ratio has gone up 77.2.
- Over the past 80 months, ZSAN's price/sales ratio has gone up 77.2.
Below are key valuation metrics over time for ZSAN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ZSAN | 2021-08-31 | 121.9 | 1.9 | -2.6 | -2.3 |
| ZSAN | 2021-08-30 | 116.4 | 1.8 | -2.5 | -2.2 |
| ZSAN | 2021-08-27 | 120.6 | 1.9 | -2.6 | -2.3 |
| ZSAN | 2021-08-26 | 120.4 | 1.9 | -2.6 | -2.3 |
| ZSAN | 2021-08-25 | 118.1 | 1.8 | -2.5 | -2.3 |
| ZSAN | 2021-08-24 | 116.1 | 1.8 | -2.5 | -2.2 |
ZSAN Growth Metrics
- The 4 year net cashflow from operations growth rate now stands at -32.23%.
- Its 2 year cash and equivalents growth rate is now at 432.25%.
- Its 3 year revenue growth rate is now at -100%.
The table below shows ZSAN's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 0.785 | -27.59 | -29.925 |
| 2021-09-30 | 0.922 | -28.041 | -31.052 |
| 2021-06-30 | 0.67 | -30.719 | -31.071 |
| 2021-03-31 | 0.482 | -30.734 | -32.822 |
| 2020-12-31 | 0.224 | -31.718 | -33.369 |
| 2020-09-30 | 0 | -32.903 | -34.211 |
ZSAN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ZSAN has a Quality Grade of F, ranking ahead of 0.35% of graded US stocks.
- ZSAN's asset turnover comes in at 0.01 -- ranking 391st of 682 Pharmaceutical Products stocks.
- HGEN, ATRA, and ARMP are the stocks whose asset turnover ratios are most correlated with ZSAN.
The table below shows ZSAN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.010 | 0.201 | -0.773 |
| 2021-03-31 | 0.007 | 0.309 | -0.821 |
| 2020-12-31 | 0.004 | 0.237 | -0.872 |
| 2020-09-30 | 0.000 | NA | -0.932 |
| 2020-06-30 | 0.000 | NA | -1.021 |
| 2020-03-31 | 0.000 | NA | -1.122 |
ZSAN Price Target
For more insight on analysts targets of ZSAN, see our ZSAN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $2.17 | Average Broker Recommendation | 1.33 (Strong Buy) |
ZSAN Stock Price Chart Interactive Chart >
ZSAN Price/Volume Stats
| Current price | $1.90 | 52-week high | $37.45 |
| Prev. close | $1.73 | 52-week low | $1.33 |
| Day low | $1.79 | Volume | 105,800 |
| Day high | $1.95 | Avg. volume | 395,711 |
| 50-day MA | $4.49 | Dividend yield | N/A |
| 200-day MA | $16.07 | Market Cap | 9.31M |
Zosano Pharma Corporation (ZSAN) Company Bio
Zosano Pharma Corporation provides biopharmaceutical products and services. The Company specializes in biopharmaceuticals, peptides, small water soluble molecules, monoclonal antibodies, and vaccines for the treatment of severe osteoporosis.
Latest ZSAN News From Around the Web
Below are the latest news stories about Zosano Pharma Corp that investors may wish to consider to help them evaluate ZSAN as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWith the long weekend over it's time to start another week of trading with the biggest pre-market stock movers for Tuesday! |
FDA Rejects Zosano Pharma's Application For Zolmitriptan Microneedle System Again, Shares PlungeThe FDA has issued a response letter to Zosano Pharma Corp (NASDAQ: ZSAN) regarding its resubmission of the 505(b)(2) New Drug Application for M207 (zolmitriptan microneedle system). The response letter stated that the FDA did not consider the resubmitted M207 application a complete response to the deficiencies identified in the FDA’s October 2020 Complete Response Letter. The FDA will not begin a substantive review of the application until a complete response is received. The FDA’s response let |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayGood morning, investor! |
Zosano Pharma Announces Pricing of $15.4 Million Public Offering of Common Stock and WarrantsFREMONT, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 51,250,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, at a public offering price of $0.30 per unit. The warrants have an exercise price of $0.30 per share, are immediately exercisable and will expire five years f |
Zosano Pharma Announces Proposed Public Offering of Common Stock and WarrantsFREMONT, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it is commencing an underwritten public offering of units consisting of shares of common stock and warrants to purchase common stock. All of the units in the offering are to be sold by Zosano. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actu |
ZSAN Price Returns
| 1-mo | N/A |
| 3-mo | -75.87% |
| 6-mo | -92.08% |
| 1-year | -92.63% |
| 3-year | -98.20% |
| 5-year | -99.79% |
| YTD | -88.45% |
| 2021 | -10.83% |
| 2020 | -65.32% |
| 2019 | -28.30% |
| 2018 | -79.62% |
| 2017 | -33.33% |
Loading social stream, please wait...